{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 33,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-based process diagram to illustrate clinical trial protocols.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/17",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Pivotal Phase 3 Trial Designs",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df5dac9c-4450-4741-8b63-0bcb320acc61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.76,
        "y": 0.315
      },
      "kind": "paragraph",
      "text": "Randomization = 2:1 Target N = 378 Topline data expected: end of 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "145d3216-759a-49da-a983-aae304030cbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.76,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Randomization = 2:1:1 Target N = 568 Topline data expected: mid-2025",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89817a12-68f4-4a19-874c-0198d7e24be8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Compass Pathways Capital Markets Day presentation as of October 12, 2022. 1. Primary endpoint = Change from baseline in MADRS total score at week 6. 2. The participant population (TRD definition and core inclusion / exclusion criteria) remains unchanged compared to phase 2b",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68af2143-a7cf-4ea9-94e7-8b4ff10c5776",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMPASS Pathways pivotal phase 3 studies are expected to deliver topline data by 2024 and 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dc03700-4f6f-4a9c-919b-a5ee111df0dd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "debb48bf-8457-4845-8ffb-3c4e7cf339c8",
      "evidence": "The slide uses a timeline-based visual to represent clinical trial phases and milestones.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}